CTi Biopharma — Cell Therapeutics — Merger or Acquisition (June 2003)
4 slides from CTi Biopharma's merger presentation, Jun 20, 2003
Slide 1: Oncology Pipeline
TRISENOX® TRISENOX® TRISENOX® APL label, > 40 trials Potential MDS label Potential myeloma label XYOTAX™ XYOTAX™ XYOTAX™ Phase III trials Potential NDA Potential NSCLC label Pixantrone Pixantrone Pixantrone Phase III trials Potential NDA Potential aggressive NHL label Oncology Pipeline Preclinical P
Slide 2: Doxorubicin, Mitoxantrone, Pixantrone
Doxorubicin Mitoxantrone Pixantrone
Slide 3: Pixantrone: Experimental cardiotoxicity
Pixantrone Experimental cardiotoxicity
Slide 4: Pixantrone: Target product profile
Pixantrone Target product profile
Cell Therapeutics — Merger or Acquisition (June 2003) on 6ix